GPC Biotech Appoints Torsten Hombeck as Chief Financial Officer

12/4/2007, 2:46 PM (Source: GlobeNewswire)



Martinsried/Munich (Germany) and Princeton, N.J., December 4, 2007 -
GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ:
GPCB) today announced the appointment of Torsten Hombeck, Ph.D., to
Chief Financial Officer. Dr. Hombeck will assume his duties on
January 1, 2008. Dr. Hombeck will replace Mirko Scherer, Ph.D., who
is resigning from the Company, effective immediately, to pursue other
interests. Dr. Scherer will remain a consultant to GPC Biotech.

Bernd R. Seizinger, M.D., Ph.D., Chief Executive Officer, said: "I
would like to express my heartfelt appreciation to Dr. Scherer, who
has worked tirelessly to build and grow GPC Biotech since he helped
to found the Company ten years ago. Dr. Scherer has played a key
role in keeping the Company well financed, which is critically
important for a biotech company. All of us at GPC Biotech warmly
wish Mirko the best in his future pursuits, and I am grateful that we
may continue to draw on his expertise."

Dr. Seizinger continued: "I am delighted that Dr. Hombeck has agreed
to become our new Chief Financial Officer. He has been with GPC
Biotech for over eight years. Dr. Hombeck has played an integral role
in our financings, including IPOs on both the Frankfurt Stock
Exchange and on NASDAQ. He was also intimately involved in our two
previous M&A transactions with Mitotix, Inc. in the U.S. and with
Axxima Pharmaceuticals in Germany. In addition, he has been
instrumental in building our Finance department and ensuring that we
meet the many reporting obligations of a dual-listed corporation.
His experience, knowledge of the Company, and the relationships and
trust he has built internally and externally will be great assets as
we move the Company forward, including our heightened focus on M&A
activities."

Torsten Hombeck, Ph.D., joined GPC Biotech in 1999. Dr. Hombeck has
worked out of the Company's U.S. offices as Vice President, Finance
since 2002, and he will continue to be based in Princeton, New
Jersey. Prior to joining GPC Biotech, he held positions in corporate
finance and controlling, including financial oversight responsibility
for South America, at Beiersdorf AG, an international branded
consumer products company. Dr. Hombeck holds a Masters degree in
business administration as well as a Ph.D. in Finance from the
European Business School, Oestrich-Winkel, Germany.

About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company with a
mission to discover, develop and commercialize new anticancer drugs.
GPC Biotech's lead product candidate is satraplatin, an oral platinum
compound. The Company has various anti-cancer programs in research
and development that leverage its expertise in kinase inhibitors. GPC
Biotech AG is headquartered in Martinsried/Munich (Germany) and has a
wholly owned U.S. subsidiary headquartered in Princeton, New Jersey.
For additional information, please visit GPC Biotech's Web site at
www.gpc-biotech.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC
Biotech, including financial projections and forecasts relating to
our operations and financial situation. Such statements are based on
current expectations and are subject to risks and uncertainties, many
of which are beyond our control, that could cause future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such
forward-looking statements. Actual results could differ materially
depending on a number of factors, and we caution investors not to
place undue reliance on the forward-looking statements contained in
this press release We direct you to GPC Biotech's Annual Report on
Form 20-F for the fiscal year ended December 31, 2006 and other
reports filed with the U.S. Securities and Exchange Commission for
additional details on the important factors that may affect the
future results, performance and achievements of GPC Biotech.
Forward-looking statements speak only as of the date on which they
are made and GPC Biotech undertakes no obligation to update these
forward-looking statements, even if new information becomes available
in the future.

For further information, please contact:

GPC Biotech AG
Martin Braendle
Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
usinvestors@gpc-biotech.com



--- End of Message ---

GPC Biotech AG
Fraunhoferstr. 20 Martinsried

WKN: 585150; ISIN:
DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX,
TECH All Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Geregelter Markt in Frankfurter Wertpapierbörse;
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.